Photo by impulsq from unsplash
Akbulak et al. (2017) recently reported results of Holter ECG monitoring (HEM) following the first dose of fingolimod in a cohort of 64 MS patients. In this small cohort, the… Click to show full abstract
Akbulak et al. (2017) recently reported results of Holter ECG monitoring (HEM) following the first dose of fingolimod in a cohort of 64 MS patients. In this small cohort, the authors reported five (7.8%) patients with new-onset transient AV-block (AVB) (ranging from firstdegree to second-degree type II (Mobitz)). In 4/5 patients (80%), the AVB could only be detected in the 72 h HEM with a median time of occurrence at 14 h. Although only one patient was symptomatic (dizziness), fingolimod treatment was discontinued in all of these mostly asymptomatic patients. There are several issues with both the methodology and the results of this study:
Journal Title: Multiple sclerosis and related disorders
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!